For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22442060.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0566 and PMC identifier 3426232.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The stromal immunoglobulin kappa chain (IGKC) has been validated as an immunologic biomarker of prognosis and response to therapy in human breast cancer and other cancers. This validation emphasizes the key role of humoral immunity in control of cancer progression and has major implications for determining prognosis of patients with cancer.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Gene Expression Profiling
- Immunoglobulins
- Ovarian Neoplasms